(300 WORDS MAX.) Despite billions of dollars invested, no new therapeutics have reached market for Alzheimer's disease (AD) in over a decade. Cx Precision Medicine, Inc. was formed on the premise that AD is a heterogeneous disease and a paradigm shift is required such that specific subpopulations are targeted for targeted interventions. One key example in the context of targeted subpopulations is the identification of those most likely to benefit from anti-diabetic medications. There is a well-established link between diabetes (DM) and AD with numerous clinical trials completed or ongoing attempting to repurpose DM medications for use in AD. However, no such trials have been successful in Phase 3. One drug that showed promise in early clinical trials was rosiglitazone (RSG). In fact, three Phase 3 trials were conducted (REFLECT trials) that failed to meet clinical outcomes. However, it is our hypothesis that these trials were in fact successful, but for specific subpopulations of AD patients. Here Cx Precision Medicine, Inc. will apply our proprietary metabolic endophenotype technology to baseline and longitudinal plasma samples from the REFLECT trials to (1) create a companion diagnostic that identifies those patients most like to benefit from RSG therapy and (2) demonstrate change in our biomarker profiles over time as a surrogate biomarker of trial outcome. Success in this work will set the stage for advancing RSG to market through established regulatory pathways as well as additional studies where Cx Precision Medicine, Inc. can assist pharmaceutical companies through clinical trials via the development of companion diagnostics. We hypothesize that the this precision medicine approach will rapidly revolutionize clinical trials in AD and other neurodegenerative diseases.